Medicago
United States
31 articles about Medicago
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
Despite having infinitely better global communications, exact figures are hard to come by for COVID-19 fatalities. Here's a look at that story and more COVID-19 news.
-
Medicago announces the appointment of Toshifumi Tada as President and CEO
4/28/2022
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, announced the appointment of Toshifumi Tada as President and chief executive officer, effective on May 1, 2022.
-
There is some evidence that COVID-19 infection might be linked to an increase in diabetes, particularly Type 1 diabetes, which is an autoimmune disease most commonly diagnosed in children.
-
Not only is this the first approval for a plant-based vaccine, it’s also the first approval for GSK’s adjuvant.
-
Medicago and GSK announce the approval by Health Canada of COVIFENZ, an Adjuvanted Plant-Based COVID-19 Vaccine
2/24/2022
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).
-
Medicago and GSK Announce the Approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine
2/24/2022
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).
-
Medicago submits Phase 3 data to Health Canada for its plant-based COVID-19 vaccine candidate
12/16/2021
Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to announce submission of the positive Phase 3 data for regulatory review by Health Canada as part of the New Drug Submission for COVID (NDS-CV) rolling review for Medicago’s COVID-19 vaccine candidate combined with GSK’s pandemic adjuvant.
-
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
5/18/2021
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline are pleased to report positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago's plant-derived COVID-19 vaccine candidate, which has been tested in combination with GSK's pandemic adjuvant.
-
Medicago and GSK announced their positive interim data from a mid-range study of a plant-based vaccine for COVID-19.
-
Health Canada initiates the review of the rolling submission for the first Canadian-based COVID-19 vaccine candidate
4/23/2021
Medicago, a biopharmaceutical company headquartered in Quebec City is pleased to announce that Health Canada received for review the first portion of Medicago's plant-derived COVID-19 vaccine candidate rolling submission on April 19, 2021.
-
Clinical Catch-Up: March 15-19
3/22/2021
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look. -
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
3/16/2021
Medicago, a biopharmaceutical company headquartered in Quebec City and GlaxoSmithKline, are pleased to announce the start of Phase 3 clinical testing of Medicago's plant-derived COVID-19 vaccine candidate in combination with GSK's pandemic adjuvant, as part of the ongoing Phase 2/3 study.
-
BioSpace Global Roundup, Nov. 12
11/12/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate
11/10/2020
Medicago, a biopharmaceutical company headquartered in Quebec City , is pleased to report interim results of the Phase 1 clinical trial of its plant-derived vaccine for COVID-19. The resu
-
Medicago signs agreements with the Government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine
10/23/2020
Canadian government to provide $173M in funding for vaccine research and development, and domestic manufacturing capacity
-
Clinical Catch-Up: July 13-17
7/20/2020
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look. -
BioSpace Global Roundup, July 16
7/16/2020
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines. -
Medicago begins Phase I clinical trials for its COVID-19 vaccine candidate
7/14/2020
Medicago, a biopharmaceutical company headquartered in Quebec City, began Phase I clinical trials for its plant-derived COVID-19 vaccine candidate yesterday, administering the first doses in healthy human volunteers